BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics
22 avr. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first...
Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
05 avr. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD
31 mars 2022 08h05 HE
|
Outlook Therapeutics, Inc.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivity ISELIN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq:...
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
03 mars 2022 08h05 HE
|
Outlook Therapeutics, Inc.
Ms. Tozier has held commercial leadership positions across the full product lifecycle and exceeded goals for 14 launches across 70-plus global markets, with deep experience in ophthalmology and...
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
24 févr. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
14 févr. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial launch planning underway Financed through...
Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
08 févr. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
Joel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and account management ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics,...
Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival
02 févr. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Provides a Corporate Update and Business Outlook
25 janv. 2022 08h05 HE
|
Outlook Therapeutics, Inc.
Outlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarterONS-5010 / LYTENAVA™...